MedScopeHub — Tool 7

Typhoid Treatment Calculator — Nigeria · Kenya · Ghana · India · Pakistan

Weight-based dosing for ceftriaxone, azithromycin, ciprofloxacin, chloramphenicol. WHO 2018 + local resistance pattern guidance. Paediatric and adult. Offline-capable.

For qualified healthcare professionals only. Doses sourced from WHO Guidelines on the Treatment of Typhoid Fever (2018) and national AMR surveillance data for each country. Resistance patterns vary by region — always send blood/stool cultures where possible. Report an error

Clinically reviewed by
Dr. Aminu Bello, FMCP
Consultant Physician & Infectious Disease Specialist, Nigeria
Updated
2025-10-01

Step 1 — Country

Step 2 — Patient Details

kg
yrs

Step 3 — Clinical Severity

Step 4 — Resistance History / Concern

Select any known or suspected resistance patterns. This updates drug recommendations. Culture results always override clinical estimation.

Quick Reference — Dose by Weight

WeightCeftriaxone (mg/day)Azithromycin (mg/day)Ciprofloxacin (mg/dose)Duration

About This Calculator

Typhoid fever remains endemic across sub-Saharan Africa and South Asia, with an estimated 11–21 million cases and 128,000–161,000 deaths annually. Nigeria, Kenya and Ghana all have high typhoid endemicity driven by poor water sanitation and food hygiene. Pakistan, India and Bangladesh report the highest burden in South Asia. Multidrug-resistant (MDR) typhoid — resistant to ampicillin, chloramphenicol, and cotrimoxazole — is now prevalent across Africa and South Asia. Extensively drug-resistant (XDR) typhoid, first identified in Sindh Province, Pakistan in 2016, has since spread across South Asia and cases have been reported in East Africa. This calculator reflects WHO typhoid management guidelines and current published resistance patterns for Nigeria, Kenya, India and Pakistan.

References & Guidelines

Frequently Asked Questions

Related calculators

📋 Guideline basis: WHO Typhoid 2011 · FMOH Nigeria · BNFc 2024  ·  Last reviewed: January 2025  ·  Next review due: January 2026  ·  Disclaimer  ·  Report an error